Neurobo Pharmaceuticals Stock Story

Requested story not found. it has been either deleted or moved. View all stories for Neurobo Pharmaceuticals.

Neurobo Pharmaceuticals Latest Timeline

Neurobo Pharmaceuticals is listed for 3.10. About 62.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.06. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurobo Pharmaceuticals recorded a loss per share of 2.46. The entity last dividend was issued on the 31st of December 2019. The firm had 1:8 split on the 21st of December 2023.

Check out Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Correlation and Neurobo Pharmaceuticals Performance. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.